The $5.50 central target is a fallback objective drawn from public technical discussion, not an analyst consensus, because ONMD lacks usable analyst price targets. ONMD trades near $4.40, so reaching $5.50 would require a roughly 25% advance, a substantial move for this micro-cap.
Distribution expansion is the near-term growth engine. A growing network of channel partners, including a recent agreement extending its reach into Korea and the Asia-Pacific region, could broaden recurring data-licensing revenue beyond its current customer base. Regulatory-grade data is a structural differentiator. OneMedNet's Imaging Real World Data (iRWD) platform is positioned to serve pharmaceutical, medical-device, and artificial intelligence (AI) developers that need high-quality, de-identified clinical imaging for drug discovery and regulatory submissions.
OneMedNet (ONMD) shares declined roughly 31% over the trailing 30 days, falling from about $6.33 to approximately $4.39. The move followed a 1-for-10 reverse stock split completed in late September 2026, a step commonly used to address exchange minimum-bid-price listing requirements.
Schrödinger (SDGR) shares rose roughly 4.5% over the trailing 30 days, but that modest net gain masked unusually wide intra-period swings. The stock climbed above $33 before retreating toward the low-$20s mid-period, then rebounded sharply in recent sessions, underscoring elevated volatility.
NRC Health is expected to report its third-quarter 2026 results in early November 2026, following a second quarter that marked a return to year-over-year revenue growth. In Q2 2026, revenue rose roughly 4% year over year to $35.4 million, while adjusted earnings per share (EPS) of $0.31 far exceeded a consensus estimate of -$0.15.
HIMS is a fast-growing, direct-to-consumer telehealth and wellness platform, while VEEV is a profitable, recurring-revenue cloud software provider for the life sciences industry. HIMS posted roughly 59% revenue growth in its most recent fiscal year but faces regulatory uncertainty tied to compounded GLP-1 (glucagon-like peptide-1) weight-loss medications.
DOCS (Doximity) is a profitable physician-focused digital network that has bounced off its lows on recent artificial intelligence (AI) product news, yet it still trades far below its 52-week high amid a securities class action and decelerating revenue growth. HNGE (Hinge Health) is a digital musculoskeletal (MSK) care platform that has outperformed since its May 2025 initial public offering (IPO), supported by rapid revenue growth and record free cash flow (FCF).
Hinge Health is scheduled to report results for its third quarter of 2026 (the period ended September 30, 2026) after the market close on Monday, November 2, 2026. Wall Street consensus points to roughly $225 million in quarterly revenue and non-GAAP earnings of about $0.58 per share .
The $130 objective examined here comes from recent, publicly reported Street research — BofA raised its target to $130 and KeyBanc to $140 — not from an analyst consensus average. The broad consensus average of roughly $112 sits almost exactly at the latest price, so it offers no meaningful upside and was not used as the central target.
MGRX is trading down roughly -15% during the regular session, near $0.25 versus a $0.2951 prior close, extending a multi-week slide. No single fresh headline drove the drop; selling reflects ongoing net losses and sharply lower revenue (~$69K in Q2 FY2026) at this speculative micro-cap.
Recurring-revenue pivot: SCWorx is shifting toward software-as-a-service (SaaS) and multi-year data-management contracts tied to healthcare ERP (enterprise resource planning) modernization, which could improve revenue visibility. Expanding customer pipeline: A series of 2026 wins — including a two-year agreement with a major Massachusetts integrated delivery network (IDN) and a Florida teaching hospital's Workday implementation — points to growing product-market fit.
WORX closed Monday's regular session at $2.68, up +94.20% from its prior close of $1.38. Primary catalyst: the company announced a new agreement with an independent, community-owned healthcare system serving New Mexico, Arizona, Colorado, and Utah for its supply chain data management services.
AIXI is Xiao-I Corporation, a China-based cognitive artificial-intelligence (AI) software provider, while MNDR is Mobile-health Network Solutions, a Singapore-based telehealth and digital-health operator. Both are micro-cap, low-float Nasdaq listings with elevated volatility, but they operate in different sectors: enterprise AI versus healthcare services.
BMBL is a U.S. online dating platform operator whose shares have been lifted recently by reports of a take-private transaction, contrasting with a multi-year decline in paying users and revenue. MNDR is a Singapore-based telehealth and telemedicine provider that trades as a micro-cap penny stock with extreme day-to-day volatility and a much smaller revenue base.
FLYE is a U.S.-based electric vehicle company selling and renting e-bikes and e-scooters, while MNDR is a Singapore-based telehealth provider operating the MaNaDr platform. Both are small-cap, early-stage companies that have experienced heavy share-price declines and undertaken capital-structure changes such as reverse stock splits (share consolidations).
BKYI and MNDR are both micro-cap, speculative names that have produced sharp, catalyst-driven price swings in recent weeks. BKYI (BIO-key International) rallied on new Middle East government security contracts, while MNDR (Mobile-health Network Solutions) spiked on limited float and heavy trading rather than a single confirmed announcement.
Different business models: MNDR is a Singapore-based AI-powered digital health (telemedicine) platform, while TCRT is a pre-clinical biotechnology company now focused on cardiopulmonary drug development. Opposing momentum: MNDR has been under sustained pressure amid shrinking revenue and listing-capital concerns, while TCRT has re-rated sharply higher after a transformative acquisition and financing.
FCHL and MNDR are both Singapore-based micro-cap companies listed on the Nasdaq, but they operate in entirely different industries — swimming education versus telehealth. Both stocks have experienced extreme share-price declines and executed reverse stock splits to maintain Nasdaq listing compliance.
Two very different businesses: MNDR is a Singapore-based AI-powered telehealth platform, while WFF is a Malaysia-based manufacturer of fiberglass reinforced plastic (FRP) products. Divergent sector exposure: MNDR operates in digital health and health technology, whereas WFF is tied to industrial manufacturing and infrastructure demand.
FLYE (Fly-E Group) is a small electric-vehicle maker facing contracting revenue, widening losses, and a shrinking cash balance, while MNDR (Mobile-health Network Solutions) is an AI health-tech platform showing improving gross margins and a strengthening cash position. Both companies are unprofitable micro-caps, but their trajectories diverge: FLYE is retrenching, while MNDR is repositioning toward an asset-light, software-driven model.